Abstract: Objective To analyze the clinical efficacy and safety of Shenyankangfupian combined with glucocorticoid in the treatment of children with Henoch-Schönlein purpura nephritis. Methods 80 children with Henoch-Schönlein purpura nephritis admitted to Affiliated Hospital of Hebei University from January 2018 to November 2018 were divided into control group(n=39)and observation group(n=41)according to the order of admission.The patients of the two groups were given symptomatic treatment such as anti-allergy, the patients in the control group were given glucocorticoid therapy, and the patients in the observation group were given Shenyankangfupian on the basis of the control group, and the treating. results of the two groups were compared. The clinical effect, clinical symptoms subsidence time, urinary protein excretion in 24-hour collections, serum IgA and adverse reactions of the patients were examined. Results There was statistically significant difference between the control group and the observation group in the clinical effect(Z=1.688, P=0.046). Compared with the control group, the clinical symptom regression time of the observation group was shortened(P<0.05). Before treatment, compared with the control group, there was no statistically significant difference in the urinary protein excretion in 24-hour collections and serum IgA level of the observation group(P>0.05). After treatment, compared with the control group, the urinary protein excretion in 24-hour collections and serum IgA level of the observation group were significantly improved. Compared with the control group(20.51%), the incidence of adverse reactions in the experimental group(2.45%)was reduced(P<0.05). Conclusion Shenyankangfupian given to children with Henoch-Schönlein purpura nephritis on the basis of glucocorticoid therapy can improve the therapeutic effect and reduce adverse reactions, improve urinary protein excretion in 24-hour collections and serum IgA shorten the time of clinical symptoms subsidence.

Key words: Shenyankangfupian, glucocorticoid, children Henoch-Schö, nlein purpura nephritis, clinical efficacy, safety